Levosimendan: current status and future prospects
- 1 February 2008
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion In Anesthesiology
- Vol. 21 (1), 78-84
- https://doi.org/10.1097/aco.0b013e3282f357a5
Abstract
While patients with acute heart failure typically receive diuretics and vasodilators, contractile dysfunction and peripheral hypoperfusion also leads to a widespread use of inotropic agents despite the lack of evidence for efficacy or safety. Levosimendan, a calcium sensitizer and vasodilator, has been proposed to be superior to standard inotropes. In addition, further possible indications for levosimendan have been described, such as perioperative use, cardioprotection, cardiogenic shock, sepsis, and right ventricular dysfunction. The mortality benefit of levosimendan has not been confirmed in two recent trials but the substance improves symptoms, decreases brain natriuretic peptide and is effective during beta-blocker treatment. The use of levosimendan as an add-on therapy in acute heart failure has been encouraged as well as its perioperative use. Levosimendan may also be useful during right ventricular dysfunction and septic shock due to its favorable effects on splanchnic perfusion. Levosimendan is an established substance in the treatment of acute heart failure in several countries despite disappointing findings concerning a possible survival benefit in two recent clinical trials. Owing to its alternative mechanisms of action as compared with traditional cardiotonic agents, several promising clinical applications have arisen. Available evidence for the use of levosimendan in settings other than decompensated heart failure is currently limited.Keywords
This publication has 67 references indexed in Scilit:
- Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart FailureJama-Journal Of The American Medical Association, 2007
- Systolic Blood Pressure at Admission, Clinical Characteristics, and Outcomes in Patients Hospitalized With Acute Heart FailureJama-Journal Of The American Medical Association, 2006
- Short-term Risk of Death After Treatment With Nesiritide for Decompensated Heart FailureJAMA, 2005
- Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart FailureCirculation, 2005
- Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of CardiologyEuropean Heart Journal, 2005
- Outcomes in heart failure patients after major noncardiac surgeryJournal of the American College of Cardiology, 2004
- Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study.Published by Oxford University Press (OUP) ,2004
- Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT studyAmerican Heart Journal, 2002
- The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure—a meta‐regression analysisEuropean Journal of Heart Failure, 2002
- Increasing awareness and improving the management of heart failure in Europe: the IMPROVEMENT of HF initiativeEuropean Journal of Heart Failure, 1999